Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma

Blood

Volumn 123, Issue 3, 2014, Pages 334-337

  Damm Welk, Christine ^a   Mussolin, Lara ^b,c   Zimmermann, Martin ^a   Pillon, Marta ^b   Klapper, Wolfram ^d   Oschlies, Ilske ^d   D'Amore, Emanuele S G ^e   Reiter, Alfred ^a   Woessmann, Wilhelm ^a,c   Rosolen, Angelo ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF PADOVA   (Italy)

^c Pediatric Research Institute   (Italy)

^d UNIVERSITY OF KIEL   (Germany)

^e SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; NUCLEOPHOSMIN;

ANTIBODY TITER; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; DISEASE-FREE SURVIVAL; HUMANS; INCIDENCE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84893120447     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-526202     Document Type: Article

References (22)

1. Brugières L., Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009; 27(6): 897-903.
2. Lowe EJ, Sposto R, Perkins S.L., et al.; Children's Cancer Group Study 5941. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer. 2009; 52(3): 335-339.
3. Rosolen A, Pillon M, Garaventa A., et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pe (Pubitemid 41579959)
4. Seidemann K, Tiemann M, Schrappe M., et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001; 97(12): 3699-3706.
5. Damm-Welk C., Klapper W, Oschlies I., et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: A molecular-histological correlation. Br J Haematol. 2009; 146(3): 306-309.
6. Perkins SL, Pickering D, Lowe E.J., et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation. Br J Haematol. 2005; 131(5): 624-627. (Pubitemid 43899628)
7. Mussolin L, Pillon M, d'Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia. 2005; 19(9): 1643-1647. (Pubitemid 43090410)
8. Damm-Welk C., Busch K, Burkhardt B., et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007; 110(2): 670-677. (Pubitemid 47105406)
9. Mussolin L, Damm-Welk C, Pillon M., et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013; 27(2): 416-422.
10. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011; 29(35): 4669-4676.
11. Le Deley M.C., Reiter A, Williams D., et al.; European Intergroup for Childhood Non-Hodgkin Lymphoma. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008; 111(3): 1560-1566. (Pubitemid 351213446)
12. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23(5): 1083-1098, vii[vii.].
13. Conter V, Bartram CR, Valsecchi M.G., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16): 3206-3214.
14. Schrappe M, Valsecchi MG, Bartram C.R., et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011; 118(8): 2077-2084.
15. Mussolin L, Pillon M, Conter V., et al. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol. 2007; 25(33): 5254-5261. (Pubitemid 350232258)
16. Le Deley M.C., Rosolen A, Williams D.M., et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010; 28(25): 3987-3993.
17. Pillon M, Gregucci F, Lombardi A., et al.; NHL-Committee of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer. 2012; 59(5): 828-833.
18. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 1141-1154.
20. Cox DR. Regression models and life tables. J R Stat Soc [Ser A]. 1972; 34: 187-200.
21. Ait-Tahar K., Damm-Welk C, Burkhardt B., et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010; 115(16): 3314-3319.
22. Mussolin L, Bonvini P, Ait-Tahar K, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia. 2009; 23(2): 400-402.